News & Resources

Overview

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$0.45
Change (%) Stock is Down 0.05 (10.00%)
Volume10,864,859
Jun 24, 2016 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
06/22/16Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
06/08/16Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave® Patent LitigationPrinter Friendly Version
06/08/16Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason Keyes to CFOPrinter Friendly Version
05/27/16Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from BoardPrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.